BACKGROUND: Previous studies on the impact of cannabis use disorders (CU) on outcome in psychosis were predominantly based on non representative samples, often have not controlled for confounders and rarely focused on adolescent patients. Thus, the aims of the present study were to assess: (i) prevalence of CU; (ii) baseline and pretreatment differences between CU and those without CU (NCU); (iii) the impact of baseline and course of CU on 18-month outcomes in a representative cohort of adolescents with early onset first episode psychosis (EOP). METHODS: The sample comprised 99 adolescents (age 14 to 18) with EOP (onset age 14 to 17), admitted to the Early Psychosis Prevention and Intervention Centre in Australia. Data were collected from medical files using a standardized questionnaire. RESULTS: Prevalence of lifetime CU was 65.7%, of current CU at baseline 53.5%, and of persistent CU throughout treatment 26.3%. Baseline CU compared to NCU had significantly higher illness-severity, lower psychosocial functioning, less insight, lower premorbid functioning and longer duration of untreated psychosis. Compared to all other groups, only persistent CU was linked to worse outcomes and more service disengagement. Effect sizes were medium controlling for relevant confounders. Medication non-adherence did not explain the association between persistent CU and worse outcome. CONCLUSIONS: Baseline CU was associated with worse baseline characteristics, but only persistent CU was linked with worse outcome. About half of those with baseline CU reduced cannabis during treatment. For these, effectively treating the psychotic disorder may already be beneficial. However, future research is necessary on the reasons for persistent CU in EOP and its treatment.
BACKGROUND: Previous studies on the impact of cannabis use disorders (CU) on outcome in psychosis were predominantly based on non representative samples, often have not controlled for confounders and rarely focused on adolescent patients. Thus, the aims of the present study were to assess: (i) prevalence of CU; (ii) baseline and pretreatment differences between CU and those without CU (NCU); (iii) the impact of baseline and course of CU on 18-month outcomes in a representative cohort of adolescents with early onset first episode psychosis (EOP). METHODS: The sample comprised 99 adolescents (age 14 to 18) with EOP (onset age 14 to 17), admitted to the Early Psychosis Prevention and Intervention Centre in Australia. Data were collected from medical files using a standardized questionnaire. RESULTS: Prevalence of lifetime CU was 65.7%, of current CU at baseline 53.5%, and of persistent CU throughout treatment 26.3%. Baseline CU compared to NCU had significantly higher illness-severity, lower psychosocial functioning, less insight, lower premorbid functioning and longer duration of untreated psychosis. Compared to all other groups, only persistent CU was linked to worse outcomes and more service disengagement. Effect sizes were medium controlling for relevant confounders. Medication non-adherence did not explain the association between persistent CU and worse outcome. CONCLUSIONS: Baseline CU was associated with worse baseline characteristics, but only persistent CU was linked with worse outcome. About half of those with baseline CU reduced cannabis during treatment. For these, effectively treating the psychotic disorder may already be beneficial. However, future research is necessary on the reasons for persistent CU in EOP and its treatment.
Authors: S M Cotton; M Lambert; B G Schimmelmann; K Filia; V Rayner; L Hides; D L Foley; A Ratheesh; A Watson; P Rodger; P D McGorry; P Conus Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2017-02-23 Impact factor: 4.328
Authors: Jennifer L Seddon; Max Birchwood; Alex Copello; Linda Everard; Peter B Jones; David Fowler; Tim Amos; Nick Freemantle; Vimal Sharma; Max Marshall; Swaran P Singh Journal: Schizophr Bull Date: 2015-11-04 Impact factor: 9.306
Authors: Leslie Marino; Samantha E Jankowski; Rick Kent; Michael L Birnbaum; Ilana Nossel; Jean-Marie Alves-Bradford; Lisa Dixon Journal: Early Interv Psychiatry Date: 2021-05-16 Impact factor: 2.732
Authors: César González-Blanch; John F Gleeson; Peter Koval; Sue M Cotton; Patrick D McGorry; Mario Alvarez-Jimenez Journal: PLoS One Date: 2015-04-07 Impact factor: 3.240
Authors: Covadonga M Díaz-Caneja; Laura Pina-Camacho; Alberto Rodríguez-Quiroga; David Fraguas; Mara Parellada; Celso Arango Journal: NPJ Schizophr Date: 2015-03-04